TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy-MedSci.cn

TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy

Bardia, A; Pusztai, L; Albain, K; Kalinsky, K; Hershman, D; Barlow, W; Tokunaga, E; Ciruelos, EM; Loirat, D; Isaacs, C; Testa, L; Dry, H; Kozarski, R; Maxwell, M; Harbeck, N; Sharma, P

BREAST, 2023; 68 (): S23

科室
- - 订阅+
  - 更多科室
工具
服务